EP4142828A1 - Ensemble micro-aiguille - Google Patents

Ensemble micro-aiguille

Info

Publication number
EP4142828A1
EP4142828A1 EP21796676.1A EP21796676A EP4142828A1 EP 4142828 A1 EP4142828 A1 EP 4142828A1 EP 21796676 A EP21796676 A EP 21796676A EP 4142828 A1 EP4142828 A1 EP 4142828A1
Authority
EP
European Patent Office
Prior art keywords
microneedle
microneedle assembly
assembly
drug compound
polymer composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21796676.1A
Other languages
German (de)
English (en)
Other versions
EP4142828A4 (fr
Inventor
Young Shin Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ticona LLC
Original Assignee
Ticona LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ticona LLC filed Critical Ticona LLC
Publication of EP4142828A1 publication Critical patent/EP4142828A1/fr
Publication of EP4142828A4 publication Critical patent/EP4142828A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14503—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1486—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
    • A61B5/6847—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
    • A61B5/685—Microneedles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/12—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L31/125—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L31/128—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix containing other specific inorganic fillers not covered by A61L31/126 or A61L31/127
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/20—Surgical instruments, devices or methods, e.g. tourniquets for vaccinating or cleaning the skin previous to the vaccination
    • A61B17/205—Vaccinating by means of needles or other puncturing devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
    • A61B2562/12—Manufacturing methods specially adapted for producing sensors for in-vivo measurements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0023—Drug applicators using microneedles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0038—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles having a channel at the side surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0046—Solid microneedles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0061—Methods for using microneedles

Definitions

  • infusion therapy is invasive, which increases the risk for infection at the infusion site and necessitates the use of pumps, transdermal tubing, etc.
  • attempts have also been to deliver vaccines through transdermal delivery devices.
  • microneedles due to their relatively small size, it is often complex to manufacture microneedles of a consistent size and shape.
  • the microneedles are often not properly aligned with each other, which can cause inconsistent delivery of the vaccine dosage.
  • a microneedle assembly comprising at least one microneedle extending outwardly from a support.
  • the microneedle includes a polymer composition containing a thermoplastic polymer having a melting temperature of about 250°C or more.
  • the polymer composition exhibits a melt viscosity of about 100 Pa-s or less and a tensile elongation of about 5% or less.
  • Fig. 1 is an SEM image of one embodiment of a microneedle assembly that may be formed in accordance with the present invention
  • FIG. 2 is a schematic plan view of one embodiment of a microneedle assembly that may be formed according to the present invention
  • FIG. 3 is a schematic front view of a line of microneedles in the assembly shown in Fig. 2;
  • FIG. 4 is a schematic front view of one embodiment of a microneedle shown in the assembly of Fig. 2;
  • Fig. 5 is a schematic side view of one embodiment of a microneedle shown in the assembly of Fig. 2;
  • Fig. 6 is a schematic plan view of one embodiment of a microneedle shown in the assembly of Fig. 2.
  • the present invention is directed to a microneedle assembly that is capable of transdermal delivery of a drug compound, such as a vaccine, (e.g., vaccine) across a dermal barrier of a subject (e.g., human), and/or detecting the presence of an analyte in the subject.
  • a drug compound such as a vaccine, (e.g., vaccine)
  • the microneedles may be formed from a thermoplastic polymer composition having a melt viscosity that is sufficiently low to enable it to be readily molded into the small dimensions required for a microneedle.
  • the polymer composition may have a melt viscosity of about 100 Pa-s or less, in some embodiments about 80 Pa-s or less, in some embodiments from about 1 Pa-s to about 60 Pa-s, and in some embodiments, from about 2 to about 50 Pa-s, as determined in accordance with ISO Test No. 11443:2014 at a shear rate at a shear rate of 1 ,000 seconds -1 at a temperature of about 30°C above the melting temperature (e.g., about 380°C).
  • the polymer composition may also have a melt viscosity of from about 150 Pa-s or less, in some embodiments about 100 Pa-s or less, in some embodiments from about 5 Pa-s to about 90 Pa-s, and in some embodiments, from about 10 to about 70 Pa-s, as determined in accordance with ISO Test No. 11443:2014 at a shear rate at a shear rate of 400 seconds -1 at a temperature of about 30°C above the melting temperature (e.g., about 380°C).
  • thermoplastic polymer compositions exhibiting such a low melt viscosity would not also possess sufficiently good thermal and mechanical properties to enable good physical integrity for use in forming microneedles that are in substantial alignment and have a consistent shape and size.
  • the present inventors have discovered through careful control of the particular thermoplastic polymer(s) and/or other optional material employed, the resulting polymer composition can also possess both excellent thermal and mechanical properties.
  • the polymer composition contains a thermoplastic polymer has a melting temperature of about 250°C or more, in some embodiments about 275°C or more, in some embodiments about 300°C or more, and in some embodiments, from about 320°C to about 450°C, such as determined in accordance with ISO 11357-2:2013.
  • the ratio of the deflection temperature under load (“DTUL”), a measure of short-term heat resistance, to the melting temperature may still remain relatively high, which can, among other things, allow the use of high-speed processes for forming the microneedles.
  • the ratio may range from about 0.5 to about 1.00, in some embodiments from about 0.65 to about 0.95, and in some embodiments from about 0.75 to about 0.85.
  • the specific DTUL values may, for instance, be about
  • 160°C or more in some embodiments from about 200°C to about 350°C, in some embodiments from about 220°C to about 320°C, and in some embodiments from about 250°C to about 300°C, such as determined in accordance with ISO Test No.
  • the polymer composition may be generally stiff in nature so that it is capable of maintaining the desired degree of physical integrity during formation of the microneedles. Such stiffness may be generally characterized by a low tensile elongation and/or a high tensile modulus.
  • the tensile elongation may be about 5% or less, in some embodiments about 4% or less, in some embodiments, from about 0.1 to about 3.5%, in some embodiments from about
  • the tensile modulus may likewise be about 7,000 MPa or more, in some embodiments about 7,500 MPa or more, in some embodiments from about
  • the polymer composition may also exhibit other good mechanical properties.
  • the polymer composition may exhibit a tensile strength of about 10 MPa or more, in some embodiments about 50 MPa or more, in some embodiments from about 70 MPa to about 300 MPa, and in some embodiments from about 80 MPa to about 200 MPa, such as determined in accordance with ISO Test No. 527:2012 at a temperature of about 23°C.
  • the polymer composition may also exhibit a flexural strength of from about 40 to about 500 MPa, in some embodiments from about 50 to about 300
  • MPa and in some embodiments, from about 100 to about 200 MPa; flexural break strain of from about 0.5% to about 15%, in some embodiments from about 0.6% to about 10%, and in some embodiments, from about 1% to about 5%; and/or flexural modulus of from about 5,000 MPa to about 20,000 MPa, in some embodiments, from about 6,000 MPa to about 15,000 MPa, and in some embodiments, from about 8,000 MPa to about 12,000 MPa.
  • the flexural properties may be determined in accordance with ISO Test No. 178:2010 (technically equivalent to
  • the composition may also exhibit a Charpy unnotched and/or notched impact strength of about 1 kJ/m 2 or more, in some embodiments from about 1.5 to about 30 kJ/m 2 , and in some embodiments, from about 2 to about 20 kJ/m 2 , measured at 23°C according to ISO Test No. 179-1:2010 (technically equivalent to ASTM D256-10e1).
  • thermoplastic polymers having the characteristics noted above may be employed in the polymer composition.
  • Particularly examples of such polymers may include, for instance, wholly or partially aromatic polymers, such as polyarylene sulfides (e.g., polyphenylene sulfide), polyamides (e.g., aromatic polyamides or semi-aromatic polyamides), polyaryleneketones (e.g., polyetheretherketone), liquid crystalline polymers, etc., as well as aliphatic polymers, such as aliphiatic polyamides.
  • polyarylene sulfides e.g., polyphenylene sulfide
  • polyamides e.g., aromatic polyamides or semi-aromatic polyamides
  • polyaryleneketones e.g., polyetheretherketone
  • liquid crystalline polymers etc.
  • aliphatic polymers such as aliphiatic polyamides.
  • Aromatic polymers are particularly suitable for use in the polymer composition.
  • the aromatic polymer can be semi-crystalline or crystalline in nature.
  • Aromatic polyamides typically contain repeating units held together by amide linkages (NH-CO) and are synthesized through the polycondensation of dicarboxylic acids (e.g., aromatic dicarboxylic acids), diamines
  • the aromatic polyamide may contain aromatic repeating units derived from an aromatic dicarboxylic acid, such as terephthalic acid, isophthalic acid, 2,6-naphthalenedicarboxylic acid, 2,7- naphthalenedicarboxylic acid, 1 ,4-naphthalenedicarboxylic acid, 1 ,4- phenylenedioxy-diacetic acid, 1 ,3-phenylenedioxy-diacetic acid, diphenic acid, 4,4'- oxydibenzoic acid, diphenylmethane-4,4'-dicarboxylic acid, diphenylsulfone-4,4'- dicarboxylic acid, 4,4'-biphenyldicarboxylic acid, etc., as well as combinations thereof.
  • aromatic dicarboxylic acid such as terephthalic acid, isophthalic acid, 2,6-naphthalenedicarboxylic acid, 2,7- naphthalenedicarboxylic acid,
  • Terephthalic acid is particularly suitable.
  • other types of acid units may also be employed, such as aliphatic dicarboxylic acid units, polyfunctional carboxylic acid units, etc.
  • the aromatic polyamide may also contain aliphatic repeating units derived from an aliphatic diamine, which typically has from 4 to 14 carbon atoms.
  • diamines include linear aliphatic alkylenediamines, such as 1 ,4- tetramethylenediamine, 1 ,6-hexanediamine, 1 ,7-heptanediamine, 1,8- octanediamine, 1 ,9-nonanediamine, 1 ,10-decanediamine, 1 ,11-undecanediamine,
  • 1 ,12-dodecanediamine, etc. branched aliphatic alkylenediamines, such as 2- methyl-1 ,5-pentanediamine, 3-methyl-1,5 pentanediamine, 2,2,4-trimethyl-1,6- hexanediamine, 2,4,4-trimethyl-1 ,6-hexanediamine, 2,4-dimethyl-1 ,6- hexanediamine, 2-methyl-1 ,8-octanediamine, 5-methyl-1 ,9-nonanediamine, etc.; as well as combinations thereof.
  • Repeating units derived from 1 ,9-nonanediamine and/or 2-methyl-1 ,8-octanediamine are particularly suitable.
  • other diamine units may also be employed, such as alicyclic diamines, aromatic diamines, etc.
  • Particularly suitable aromatic polyamides may include polyfnonamethylene terephthalamide) (PA9T), poly(nonamethylene terephthalamide/nonamethylene decanediamide) (PA9T/910), poly(nonamethylene terephthalamide/nonamethylene dodecanediamide) (PA9T/912), poly(nonamethylene terephthalamide/11 -aminoundecanamide) (PA9T/11 ), poly(nonamethylene terephthalamide/12-aminododecanamide) (PA9T/12), poly(decamethylene terephthalamide/11 -aminoundecanamide) (PA 10T/11), poly(decamethylene terephthalamide/12-aminododecanamide) (PA10T/12), poly(decamethylene terephthalamide/decamethylene decanediamide) (PA10T/1010), poly(decamethylene terephthalamide/decamethylene dodecanediamide) (PA10T/1010), poly
  • PA12T/1212 poly(dodecamethylene terephthalamide/caprolactam) (PA12T/6), poly(dodecamethylene terephthalamide/hexamethylene hexanediamide)
  • polyaryletherketone Another suitable semi-crystalline aromatic polymer that may be employed in the present invention is a polyaryletherketone.
  • Particularly suitable polyaryletherketones are those that primarily include phenyl moieties in conjunction with ketone and/or ether moieties. Examples of such polymers include polyetheretherketone (“PEEK”), polyetherketone (“PEK”), polyetherketoneketone (“PEKK”), polyetherketoneetherketoneketone (“PEKEKK”), polyetheretherketoneketone (“PEEKK”), polyether-diphenyl-ether-ether-diphenyl- ether-phenyl-ketone-phenyl, etc., as well as blends and copolymers thereof.
  • PEEK polyetheretherketone
  • PEK polyetherketone
  • PEKK polyetherketoneketone
  • PEKEKK polyetherketoneketoneketone
  • PEEKK polyether-diphenyl-ether-ether-diphenyl- ether-phenyl-ket
  • thermoplastic polymers for use in the polymer composition are liquid crystalline polymers.
  • Liquid crystalline polymers are generally classified as “thermotropic” to the extent that they can possess a rod-like structure and exhibit a crystalline behavior in their molten state (e.g., thermotropic nematic state).
  • Such polymers may be formed from one or more types of repeating units as is known in the art.
  • a liquid crystalline polymer may, for example, contain one or more aromatic ester repeating units generally represented by the following Formula (I): wherein, ring B is a substituted or unsubstituted 6-membered aryl group (e.g., 1,4- phenylene or 1 ,3-phenylene), a substituted or unsubstituted 6-membered aryl group fused to a substituted or unsubstituted 5- or 6-membered aryl group (e.g., 2,6-naphthalene), or a substituted or unsubstituted 6-membered aryl group linked to a substituted or unsubstituted 5- or 6-membered aryl group (e.g., 4,4- biphenylene); and
  • Formula (I) wherein, ring B is a substituted or unsubstituted 6-membered aryl group (e.g., 1,4- phenylene or 1 ,3-phenylene), a substitute
  • Yi and Y2 are independently 0, C(O), NH, C(0)HN, or NHC(O).
  • At least one of Yi and Y2 are C(O).
  • aromatic ester repeating units may include, for instance, aromatic dicarboxylic repeating units (Yi and Y2 in Formula I are C(O)), aromatic hydroxycarboxylic repeating units (Yi is O and Y2 is C(O) in Formula I), as well as various combinations thereof.
  • Aromatic hydroxycarboxylic repeating units may be employed that are derived from aromatic hydroxycarboxylic acids, such as, 4- hydroxybenzoic acid; 4-hydroxy-4'-biphenylcarboxylic acid; 2-hydroxy-6-naphthoic acid; 2-hydroxy-5-naphthoic acid; 3-hydroxy-2-naphthoic acid; 2-hydroxy-3- naphthoic acid; 4'-hydroxyphenyl-4-benzoic acid; 3'-hydroxyphenyl-4-benzoic acid; 4'-hydroxyphenyl-3-benzoic acid, etc., as well as alkyl, alkoxy, aryl and halogen substituents thereof, and combination thereof.
  • aromatic hydroxycarboxylic acids such as, 4- hydroxybenzoic acid; 4-hydroxy-4'-biphenylcarboxylic acid; 2-hydroxy-6-naphthoic acid; 2-hydroxy-5-naphthoic acid; 3-hydroxy-2-naphthoic acid; 2-
  • aromatic hydroxycarboxylic acids are 4-hydroxybenzoic acid (“HBA”) and 6-hydroxy-2- naphthoic acid (“HNA”).
  • HBA and/or HNA repeating units derived from hydroxycarboxylic acids typically constitute about 20 mol.% or more, in some embodiments about 25 mol.% or more, in some embodiments about 30 mol.% or more, in some embodiments about 40 mol.% or more, in some embodiments about 50 mole% or more, in some embodiments from about 55 mol.% to 100 mol.%, and in some embodiments, from about 60 mol.% to about 95 mol.% of the polymer.
  • Aromatic dicarboxylic repeating units may also be employed that are derived from aromatic dicarboxylic acids, such as terephthalic acid, isophthalic acid, 2,6-naphthalenedicarboxylic acid, diphenyl ether-4, 4'-dicarboxylic acid, 1 ,6- naphthalenedicarboxylic acid, 2,7-naphthalenedicarboxylic acid, 4,4'- dicarboxybiphenyl, bis(4-carboxyphenyl)ether, bis(4-carboxyphenyl)butane, bis(4- carboxyphenyl)ethane, bis(3-carboxyphenyl)ether, bis(3-carboxyphenyl)ethane, etc., as well as alkyl, alkoxy, aryl and halogen substituents thereof, and combinations thereof.
  • aromatic dicarboxylic acids such as terephthalic acid, isophthalic acid, 2,6-naphthalenedicarboxy
  • aromatic dicarboxylic acids may include, for instance, terephthalic acid (“TA”), isophthalic acid (“IA”), and 2,6- naphthalenedicarboxylic acid (“NDA”).
  • TA terephthalic acid
  • IA isophthalic acid
  • NDA 2,6- naphthalenedicarboxylic acid
  • repeating units derived from aromatic dicarboxylic acids each typically constitute from about 1 mol.% to about 40 mol.%, in some embodiments from about 2 mol.% to about 30 mol.%, and in some embodiments, from about 5 mol.% to about 25% of the polymer.
  • repeating units may also be employed in the polymer.
  • repeating units may be employed that are derived from aromatic diols, such as hydroquinone, resorcinol, 2,6- dihydroxynaphthalene, 2,7-dihydroxynaphthalene, 1 ,6-dihydroxynaphthalene, 4,4'- dihydroxybiphenyl (or 4,4’-biphenol), 3,3'-dihydroxybiphenyl, 3,4'- dihydroxybiphenyl, 4,4'-dihydroxybiphenyl ether, bis(4-hydroxyphenyl)ethane, etc., as well as alkyl, alkoxy, aryl and halogen substituents thereof, and combinations thereof.
  • aromatic diols such as hydroquinone, resorcinol, 2,6- dihydroxynaphthalene, 2,7-dihydroxynaphthalene, 1 ,6-dihydroxynaphthalene, 4,4'- dihydroxybipheny
  • aromatic diols may include, for instance, hydroquinone (“HQ”) and 4,4’-biphenol (“BP”).
  • HQ hydroquinone
  • BP 4,4’-biphenol
  • repeating units derived from aromatic diols typically constitute from about about 1 mol.% to about 50 mol.%, in some embodiments from about 1 to about 40 mol.%, in some embodiments from about 2 mol.% to about 40 mol.%, in some embodiments from about 5 mol.% to about 35 mol.%, and in some embodiments, from about 5 mol.% to about 25% of the polymer.
  • Repeating units may also be employed, such as those derived from aromatic amides (e.g., acetaminophen (“APAP”)) and/or aromatic amines (e.g., 4- aminophenol (“AP”), 3-aminophenol, 1 ,4-phenylenediamine, 1,3- phenylenediamine, etc.).
  • aromatic amides e.g., APAP
  • aromatic amines e.g., AP
  • repeating units derived from aromatic amides (e.g., APAP) and/or aromatic amines (e.g., AP) typically constitute from about 0.1 mol.% to about 20 mol.%, in some embodiments from about 0.5 mol.% to about 15 mol.%, and in some embodiments, from about 1 mol.% to about 10% of the polymer.
  • the polymer may contain one or more repeating units derived from non-aromatic monomers, such as aliphatic or cycloaliphatic hydroxycarboxylic acids, dicarboxylic acids, diols, amides, amines, etc.
  • non-aromatic monomers such as aliphatic or cycloaliphatic hydroxycarboxylic acids, dicarboxylic acids, diols, amides, amines, etc.
  • the polymer may be “wholly aromatic” in that it lacks repeating units derived from non-aromatic (e.g., aliphatic or cycloaliphatic) monomers.
  • the liquid crystalline polymer may be a “high naphthenic” polymer to the extent that it contains a relatively high content of repeating units derived from naphthenic hydroxycarboxylic acids and naphthenic dicarboxylic acids, such as NDA, HNA, or combinations thereof.
  • the total amount of repeating units derived from naphthenic hydroxycarboxylic and/or dicarboxylic acids is typically about 10 mol.% or more, in some embodiments about 12 mol.% or more, in some embodiments about 15 mol.% or more, in some embodiments about 18 mol.% or more, in some embodiments about 30 mol.% or more, in some embodiments about
  • such high naphthenic polymers typically have a water adsorption of about 0.015% or less, in some embodiments about 0.01% or less, and in some embodiments, from about 0.0001% to about 0.008% after being immersed in water for 24 hours in accordance with ISO 62-1 :2008.
  • the high naphthenic polymers may also have a moisture adsorption of about 0.01% or less, in some embodiments about 0.008% or less, and in some embodiments, from about 0.0001% to about 0.006% after being exposed to a humid atmosphere (50% relative humidity) at a temperature of 23°C in accordance with ISO 62-4:2008.
  • HNA may constitute 30 mol.% or more, in some embodiments about 40 mol.% or more, in some embodiments about 45 mol.% or more, in some embodiments 50 mol.% or more, in some embodiments about 55 mol.% or more, and in some embodiments, from about 55 mol.% to about 95 mol.% of the polymer.
  • the liquid crystalline polymer may contain various other monomers, such as aromatic hydroxycarboxylic acid(s) (e.g., HBA) in an amount of from about
  • aromatic dicarboxylic acid(s) e.g., IA and/or TA
  • aromatic diol(s) e.g., BP and/or HQ
  • the repeating units derived from NDA may constitute 10 mol.% or more, in some embodiments about 12 mol.% or more, in some embodiments about 15 mol.% or more, and in some embodiments, from about 18 mol.% to about 95 mol.% of the polymer.
  • the liquid crystalline polymer may also contain various other monomers, such as aromatic hydroxycarboxylic acid(s) (e.g., HBA) in an amount of from about 20 mol.% to about 60 mol.%, and in some embodiments, from about
  • aromatic hydroxycarboxylic acid(s) e.g., HBA
  • aromatic dicarboxylic acid(s) e.g., IA and/or TA
  • aromatic diol(s) e.g., BP and/or HQ
  • “low naphthenic” liquid crystalline polymers may also be employed in the composition, either alone or in combination with “high naphthenic” liquid crystalline polymers.
  • the total amount of repeating units derived from naphthenic hydroxycarboxylic and/or dicarboxylic acids is typically less than 10 mol.%, in some embodiments about 8 mol.% or less, in some embodiments about 6 mol.% or less, and in some embodiments, from about 1 mol.% to about 5 mol.% of the polymer.
  • the liquid crystalline polymer may be prepared by initially introducing the aromatic monomer(s) used to form the ester repeating units (e.g., aromatic hydroxycarboxylic acid, aromatic dicarboxylic acid, etc.) and/or other repeating units (e.g., aromatic diol, aromatic amide, aromatic amine, etc.) into a reactor vessel to initiate a polycondensation reaction.
  • aromatic monomer(s) used to form the ester repeating units e.g., aromatic hydroxycarboxylic acid, aromatic dicarboxylic acid, etc.
  • other repeating units e.g., aromatic diol, aromatic amide, aromatic amine, etc.
  • the vessel employed for the reaction is not especially limited, although it is typically desired to employ one that is commonly used in reactions of high viscosity fluids.
  • a reaction vessel may include a stirring tank-type apparatus that has an agitator with a variably-shaped stirring blade, such as an anchor type, multistage type, spiral-ribbon type, screw shaft type, etc., or a modified shape thereof.
  • Further examples of such a reaction vessel may include a mixing apparatus commonly used in resin kneading, such as a kneader, a roll mill, a Banbury mixer, etc.
  • the reaction may proceed through the acetylation of the monomers as known the art. This may be accomplished by adding an acetylating agent (e.g., acetic anhydride) to the monomers.
  • acetylation is generally initiated at temperatures of about 90°C.
  • reflux may be employed to maintain vapor phase temperature below the point at which acetic acid byproduct and anhydride begin to distill. Temperatures during acetylation typically range from between 90°C to 150°C, and in some embodiments, from about 110°C to about 150°C. If reflux is used, the vapor phase temperature typically exceeds the boiling point of acetic acid, but remains low enough to retain residual acetic anhydride.
  • acetic anhydride vaporizes at temperatures of about 140°C.
  • providing the reactor with a vapor phase reflux at a temperature of from about 110°C to about 130°C is particularly desirable.
  • an excess amount of acetic anhydride may be employed. The amount of excess anhydride will vary depending upon the particular acetylation conditions employed, including the presence or absence of reflux. The use of an excess of from about 1 to about 10 mole percent of acetic anhydride, based on the total moles of reactant hydroxyl groups present is not uncommon.
  • Acetylation may occur in in a separate reactor vessel, or it may occur in situ within the polymerization reactor vessel.
  • one or more of the monomers may be introduced to the acetylation reactor and subsequently transferred to the polymerization reactor.
  • one or more of the monomers may also be directly introduced to the reactor vessel without undergoing pre-acetylation.
  • a catalyst may be optionally employed, such as metal salt catalysts (e.g., magnesium acetate, tin(l) acetate, tetrabutyl titanate, lead acetate, sodium acetate, potassium acetate, etc.) and organic compound catalysts (e.g., N-methylimidazole).
  • metal salt catalysts e.g., magnesium acetate, tin(l) acetate, tetrabutyl titanate, lead acetate, sodium acetate, potassium acetate, etc.
  • organic compound catalysts e.g., N-methylimidazole
  • the reaction mixture is generally heated to an elevated temperature within the polymerization reactor vessel to initiate melt polycondensation of the reactants.
  • Polycondensation may occur, for instance, within a temperature range of from about 250°C to about 380°C, and in some embodiments, from about 280°C to about 380°C.
  • one suitable technique for forming the aromatic polyester may include charging precursor monomers and acetic anhydride into the reactor, heating the mixture to a temperature of from about 90°C to about 150°C to acetylize a hydroxyl group of the monomers (e.g., forming acetoxy), and then increasing the temperature to from about 280°C to about 380°C to carry out melt polycondensation.
  • volatile byproducts of the reaction may also be removed so that the desired molecular weight may be readily achieved.
  • the reaction mixture is generally subjected to agitation during polymerization to ensure good heat and mass transfer, and in turn, good material homogeneity.
  • the rotational velocity of the agitator may vary during the course of the reaction, but typically ranges from about 10 to about 100 revolutions per minute (“rpm”), and in some embodiments, from about 20 to about 80 rpm.
  • the polymerization reaction may also be conducted under vacuum, the application of which facilitates the removal of volatiles formed during the final stages of polycondensation.
  • the vacuum may be created by the application of a suctional pressure, such as within the range of from about 5 to about 30 pounds per square inch (“psi”), and in some embodiments, from about 10 to about 20 psi.
  • the molten polymer may be discharged from the reactor, typically through an extrusion orifice fitted with a die of desired configuration, cooled, and collected. Commonly, the melt is discharged through a perforated die to form strands that are taken up in a water bath, pelletized and dried. In some embodiments, the melt polymerized polymer may also be subjected to a subsequent solid-state polymerization method to further increase its molecular weight. Solid-state polymerization may be conducted in the presence of a gas (e.g., air, inert gas, etc.).
  • a gas e.g., air, inert gas, etc.
  • Suitable inert gases may include, for instance, include nitrogen, helium, argon, neon, krypton, xenon, etc., as well as combinations thereof.
  • the solid-state polymerization reactor vessel can be of virtually any design that will allow the polymer to be maintained at the desired solid-state polymerization temperature for the desired residence time. Examples of such vessels can be those that have a fixed bed, static bed, moving bed, fluidized bed, etc.
  • the temperature at which solid-state polymerization is performed may vary, but is typically within a range of from about 250°C to about 350°C.
  • the polymerization time will of course vary based on the temperature and target molecular weight. In most cases, however, the solid-state polymerization time will be from about 2 to about 12 hours, and in some embodiments, from about 4 to about 10 hours.
  • the thermoplastic polymers may constitute the entire polymer composition (e.g., 100 wt.%). Nevertheless, it may be desirable in certain embodiments to include one or more additives within the polymer composition to help achieve the target properties.
  • the polymer composition typically contains one or more thermoplastic polymers (e.g., liquid crystalline polymers) in an amount of from about 30 wt.% to about 99 wt.%, in some embodiments from about 40 wt.% to about 95 wt.%, and in some embodiments, from about 50 wt.% to about 90 wt.% of the entire polymer composition, as well as one or more additives in an amount of from about 1 wt.% to about 70 wt.%, in some embodiments from about 5 wt.% to about 60 wt.%, and in some embodiments, from about 10 wt.% to about 50 wt.% of the polymer composition.
  • thermoplastic polymers e.g., liquid crystalline polymers
  • the polymer composition may contain a mineral filler, which may be in the form of particles (e.g., platelet-shaped, flake-shaped, etc.), fibers, and so forth.
  • the mineral filler may include a particulate mineral filler, such as talc, halloysite, kaolinite, illite, montmorillonite, vermiculite, palygorskite, pyrophyllite, mica, diatomaceous earth, etc., as well as combinations thereof. Mica and/or talc may be particularly suitable.
  • particulate mineral fillers of a relatively small size better aid in filling of a mold cavity, as well as ensuring proper microneedle alignment.
  • the particulate mineral filler e.g., talc
  • mineral filler particles may include carbonates, such as calcium carbonate (CaCCte) or a copper carbonate hydroxide (Cu2C03(0H)2); fluorides, such as calcium fluoride (CaF ); phosphates, such as calcium pyrophosphate (Ca2P207), anhydrous dicalcium phosphate (CaHPC ), or hydrated aluminum phosphate (AIPO4 2H2O); glass (e.g., glass powder); etc.
  • Mineral fibers also known as “whiskers” may also be employed as a mineral filler in the polymer composition.
  • mineral fibers examples include those that are derived from silicates, such as neosilicates, sorosilicates, inosilicates (e.g., calcium inosilicates, such as wollastonite; calcium magnesium inosilicates, such as tremolite; calcium magnesium iron inosilicates, such as actinolite; magnesium iron inosilicates, such as anthophyllite; etc.), phyllosilicates (e.g., aluminum phyllosilicates, such as palygorskite), tectosilicates, etc.; sulfates, such as calcium sulfates (e.g., dehydrated or anhydrous gypsum); mineral wools (e.g., rock or slag wool); glass; and so forth.
  • silicates such as neosilicates, sorosilicates, inosilicates (e.g., calcium inosilicates,
  • the mineral fibers may also have a relatively high aspect ratio (average length divided by median width) to help further improve the mechanical properties.
  • the mineral fibers may have an aspect ratio of from about 1 to about 50, in some embodiments from about 2 to about 20, and in some embodiments, from about 4 to about 15.
  • the volume average length of such mineral fibers may, for example, range from about 1 to about 200 micrometers, in some embodiments from about 2 to about 150 micrometers, in some embodiments from about 5 to about 100 micrometers, and in some embodiments, from about 10 to about 50 micrometers.
  • a tribological additive material may also be employed in the polymer composition to help achieve a good combination of low friction and good wear resistance for use in the microneedle assembly.
  • the tribological additive material may include a fluorinated additive.
  • the fluorinated additive can, among other things, improve the processing of the composition, such as by providing better mold filling, internal lubrication, mold release, etc.
  • the fluorinated additive may include a fluoropolymer, which contains a hydrocarbon backbone polymer in which some or all of the hydrogen atoms are substituted with fluorine atoms.
  • the backbone polymer may polyolefinic and formed from fluorine-substituted, unsaturated olefin monomers.
  • the fluoropolymer can be a homopolymer of such fluorine-substituted monomers or a copolymer of fluorine-substituted monomers or mixtures of fluorine- substituted monomers and non-fluorine-substituted monomers.
  • the fluoropolymer can also be substituted with other halogen atoms, such as chlorine and bromine atoms.
  • Representative monomers suitable for forming fluoropolymers for use in this invention are tetrafluoroethylene, vinylidene fluoride, hexafluoropropylene, chlorotrifluoroethylene, perfluoroethylvinyl ether, perfluoromethylvinyl ether, perfluoropropylvinyl ether, etc., as well as mixtures thereof.
  • fluoropolymers include polytetrafluoroethylene, perfluoroalkylvinyl ether, poly(tetrafluoroethylene- co-perfluoroalkyvinylether), fluorinated ethylene-propylene copolymer, ethylene- tetrafluoroethylene copolymer, polyvinylidene fluoride, polychlorotrifluoroethylene, etc., as well as mixtures thereof.
  • the fluorinated additive may contain only the fluoropolymer, or it may also include other ingredients, such as those that aid in its ability to be uniformly dispersed within the polymer composition.
  • the fluorinated additive may include a fluoropolymer in combination with a plurality of carrier particles.
  • the fluoropolymer may be coated onto the carrier particles.
  • Silicate particles are particularly suitable for this purpose, such as talc, halloysite, kaolinite, illite, montmorillonite, vermiculite, palygorskite, pyrophyllite, calcium silicate, aluminum silicate, mica, diatomaceous earth, wollastonite, and so forth.
  • Mica for instance, may be a particularly suitable mineral for use in the present invention.
  • the carrier particles may have an average particle size of from about 5 to about 50 micrometers, and in some embodiments, from about 10 to 20 micrometers. If desired, the carrier particles may also be in the shape of plate-like particles in that the ratio of its major axis to thickness is 2 or more.
  • a wide variety of other additional additives can also be included in the polymer composition, such as lubricants, fibrous fillers (e.g., glass fibers), thermally conductive fillers, pigments, antioxidants, stabilizers, surfactants, waxes, flame retardants, anti-drip additives, nucleating agents (e.g., boron nitride), flow modifiers, coupling agents, antimicrobials, pigments or other colorants, impact modifiers, and other materials added to enhance properties and processability.
  • lubricants e.g., glass fibers
  • fibrous fillers e.g., glass fibers
  • thermally conductive fillers e.g., pigments, antioxidants, stabilizers, surfactants, waxes, flame retardants, anti-drip additives
  • nucleating agents e.g., boron nitride
  • flow modifiers e.g., coupling agents, antimicrobials, pigments or other colorants, impact modifiers, and other
  • the components used to form the polymer composition may be combined together using any of a variety of different techniques as is known in the art.
  • the thermoplastic polymer and other optional additives are melt processed as a mixture within an extruder to form the polymer composition.
  • the mixture may be melt-kneaded in a single-screw or multi-screw extruder at a temperature of from about 200°C to about 450°C.
  • the mixture may be melt processed in an extruder that includes multiple temperature zones. The temperature of individual zones is typically set within about -60°C to about 25°C relative to the melting temperature of the polymer.
  • the mixture may be melt processed using a twin screw extruder such as a Leistritz 18-mm co-rotating fully intermeshing twin screw extruder.
  • a general purpose screw design can be used to melt process the mixture.
  • the mixture including all of the components may be fed to the feed throat in the first barrel by means of a volumetric feeder.
  • different components may be added at different addition points in the extruder, as is known.
  • the polymer may be applied at the feed throat, and certain additives (e.g., particulate filler) may be supplied at the same or different temperature zone located downstream therefrom.
  • the resulting mixture can be melted and mixed then extruded through a die.
  • the extruded polymer composition can then be quenched in a water bath to solidify and granulated in a pelletizer followed by drying.
  • the microneedle assembly typically includes one or more microneedles that extend outwardly from a support. Any of a variety of techniques may be employed to form the microneedles, such as embossing (e.g., hot embossing, roll-to-roll molding, etc.); molding, such as micro-molding, injection molding (e.g. low-pressure injection molding, gas injection molding, foam injection molding, etc.), compression molding (e.g., extrusion compression molding), extrusion molding; printing (e.g., three-dimensional printing); and so forth. For example, an injection molding system may be employed that includes a mold within which the polymer composition may be injected.
  • embossing e.g., hot embossing, roll-to-roll molding, etc.
  • molding such as micro-molding, injection molding (e.g. low-pressure injection molding, gas injection molding, foam injection molding, etc.), compression molding (e.g., extrusion compression molding), extrusion molding; printing (e
  • the time inside the injector may be controlled and optimized so that polymer matrix is not pre solidified.
  • a piston may be used to inject the composition to the mold cavity.
  • Compression molding systems may also be employed.
  • injection molding the shaping of the polymer composition into the desired article also occurs within a mold.
  • the composition may be placed into the compression mold using any known technique, such as by being picked up by an automated robot arm.
  • the temperature of the mold may be maintained at or above the solidification temperature of the polymer matrix for a desired time period to allow for solidification.
  • the molded product may then be solidified by bringing it to a temperature below that of the melting temperature.
  • the resulting product may be de-molded.
  • the cycle time for each molding process may be adjusted to suit the polymer matrix, to achieve sufficient bonding, and to enhance overall process productivity.
  • a microneedle assembly 500 contains a plurality of microneedles 510 (e.g., array of microneedles) that extend outwardly from a support 520.
  • the microneedles 510 may be formed from the polymer composition of the present invention.
  • the support 520 may also be formed from the polymer composition, as well as from a rigid or flexible sheet of metal, ceramic, plastic, or other material.
  • the support 520 can vary in thickness to meet the needs of the particular drug delivery application, such as about 1000 micrometers or less, in some embodiments from about 1 to about 500 micrometers, and in some embodiments, from about 10 to about 200 micrometers.
  • the density of the microneedles 510 may vary as desired, such as about 2,000 microneedles per square centimeter (cm 2 ) or more, in some embodiments from about 3,000 to about 25,000 microneedles per cm 2 , and in some embodiments, from about 5,000 to about 20,000 microneedles per cm 2 .
  • the number of microneedles 510 used in the assembly 500 may, for example, range from about 500 to about 10,000, in some embodiments from about 2,000 to about
  • microneedles 510 may be arranged on the support 520 in a variety of patterns.
  • the microneedles may be spaced apart in a uniform manner, such as in a rectangular or square grid or in concentric circles, or they may be arranged in one or more lines. While a variety of arrangements may be employed, a particularly suitable embodiment is shown in Fig. 2 in which the microneedles 510 are arranged in straight, spaced apart lines. The spacing may depend on numerous factors, including height and width of the microneedles 510, as well as the amount and type of substance that is intended to be moved through the microneedles. For example, the spacing between the tips of the microneedles 510 (Si in Fig.
  • the spacing between the bases of the microneedles 510 may be from about 50 micrometers or more, in some embodiments about 100 to about 1,000 micrometers, and in some embodiments, from about 200 to about 800 micrometers.
  • the size and shape of the microneedles 510 may also vary as desired.
  • the microneedles 510 are shown as having a tapering hexagonal shape that contains a tip 611 and a base 612.
  • the base 612 has two substantially parallel sides 621 and 622, with a slight draught angle as indicated in Fig. 5 by CM up to a transition point 613 at which point the angle increases as indicated in Fig. 5 by 02).
  • this example depicts a distinct increase in the angle at the transition point 613, it should be noted that there may be a more gradual increase in the angle than depicted.
  • the draught angle CM may, for instance, range from about 0 to 20 degrees, in some embodiments from about 0 to 15 degrees, in some embodiments from about 1 to about 15 degrees, and in some embodiments, from about 2 to about 10 degrees.
  • the transition point angle 02 may range from about 20 to 70 degrees, in some embodiments from about 20 to 60 degrees, in some embodiments from about 25 to about 55 degrees, and in some embodiments, from about 25 to about 45 degrees.
  • the ends of the microneedles may be blunted to provide an extended octagonal profile. While the profiles of the microneedles may define extended hexagonal or octagonal shapes, the edges of the profiles may be somewhat rounded depending on the method of manufacture of the microneedles and microneedle arrays.
  • the tip 611 of each microneedle 510 terminates in an elongate edge.
  • the tip 611 has a width Wtip and a length Up.
  • the length of the tip may range from about 5 to about 500 nanometers, in some embodiments from about 10 to about 200 nanometers, and in some embodiments, from about 20 to about 100 nanometers, while the width of the tip may range from about 0.5 to about 5 micrometers, in some embodiments from about 0.6 to about 4 micrometers, and in some embodiments, from about 1 to about 3.5 micrometers.
  • the base 612 has a and a thickness Tbase and length Uase, which is greater in length than the tip 611.
  • the base of the microneedles may have a length of from about 10 to about 1 ,000 nanometers, in some embodiments from about 20 to about 500 nanometers, and in some embodiments, from about 30 to about 100 nanometers, while the thickness of the base may be from about 5 to about 100 nanometers, in some embodiments from about 10 to about 80 nanometers, and in some embodiments, from about 20 to about 70 nanometers.
  • the cross-sectional length:thickness aspect ratio of the base 612 (Uase base) may likewise be relatively high, such as about 2:1 or more, in some embodiments from about 2:1 to about 20:1, and in some embodiments, from about 3:1 to about 10:1.
  • Each microneedle also has an overall height H that is of a length sufficient to penetrate through at least the outermost layer of the epidermis (i.e. , stratum corneum), but optionally not so great that they pass through the dermis.
  • the height may be from about 10 to about 1 ,000 nanometers, in some embodiments from about 20 to about 500 nanometers, and in some embodiments, from about 30 to about 100 nanometers.
  • the manner in which the microneedle assembly delivers the drug compound may vary as is known in the art.
  • the drug compound may be coated onto a surface of the microneedle.
  • Various coating techniques may be employed, such as dipping, spraying, printing (e.g., inkjet printing, spotting, non-contact printing, drop-on-demand piezoelectric micro dispensing, etc.), and so forth.
  • the microneedles may be dipped into a drug compound reservoir through dip holes that are spaced in accordance with the microneedle array.
  • the microneedles may also be spray coated with the drug compound and then dried with a gas.
  • the microneedles may be coated with the drug compound through a printing technique.
  • a piezoelectric stack actuator may be employed as a driving component that dispenses a fluidic drug compound (or fluid containing the compound) from a pumping chamber though a two-dimensional array of nozzles.
  • the nozzles are aligned with the microneedles so that the dispensed fluid is coated onto a surface thereof.
  • the microneedles may be solid in nature, and thus be free of hollow channels and/or pores for fluid delivery.
  • the microneedle assembly does not require conventional components (e.g., drug reservoirs, release members, etc.) to drive the delivery of the drug compound.
  • conventional components e.g., drug reservoirs, release members, etc.
  • solid microneedles are described, for instance, in U.S. Patent Publication No. 2018/0264244 to Meliga, et al., which is incorporated herein in its entirety by reference thereto.
  • one or more of the microneedles may contain one or more channels of a certain dimension such that passive capillary flow can drive the delivery of the drug compound.
  • the microneedles may define at least one channel that is in fluidic communication with a drug compound, such as through an aperture of the support.
  • a channel 511 is located on an exterior surface of the microneedles 510. Although shown on an exterior surface, the channel may be located in a variety of different positions, such as in the interior of the microneedle.
  • the dimensions of the channel are specifically selected in the present invention to induce capillary flow of the drug compound.
  • Capillary flow generally occurs when the adhesive forces of a fluid to the walls of a channel are greater than the cohesive forces between the liquid molecules.
  • capillary pressure is inversely proportional to the cross-sectional dimension of the channel and directly proportional to the surface tension of the liquid, multiplied by the cosine of the contact angle of the fluid in contact with the material forming the channel.
  • the cross-sectional dimension (e.g., width, diameter, etc.) of the channel may be selectively controlled, with smaller dimensions generally resulting in higher capillary pressure.
  • the cross-sectional dimension of the channel may range from about 1 micrometer to about 100 micrometers, in some embodiments from about 5 micrometers to about
  • the dimension may be constant or it may vary as a function of the length of the channel.
  • the length of the channel may also vary to accommodate different volumes, flow rates, and dwell times for the drug compound.
  • the length of the channel may be from about 10 micrometers to about 800 micrometers, in some embodiments from about 50 micrometers to about 500 micrometers, and in some embodiments, from about 100 micrometers to about 300 micrometers.
  • the cross-sectional area of the channel may also vary.
  • the cross-sectional area may be from about 50 square micrometers to about 1,000 square micrometers, in some embodiments from about 100 square micrometers to about 500 square micrometers, and in some embodiments, from about 150 square micrometers to about 350 square micrometers.
  • the aspect ratio (length/cross-sectional dimension) of the channel may range from about 1 to about 50, in some embodiments from about 5 to about 40, and in some embodiments from about 10 to about 20. In cases where the cross-sectional dimension (e.g., width, diameter, etc.) and/or length vary as a function of length, the aspect ratio is determined from the average dimensions.
  • the microneedle assembly can deliver a controlled volume of a drug compound through the skin.
  • the microneedle assembly may be placed adjacent to the skin of a subject (e.g., human) and pressure may be applied thereto so that the microneedles penetrate into at least the stratum corneum of the epidermis.
  • the microneedle assembly may be placed in fluid communication with a reservoir that can initially retain the drug compound, particular in those embodiments which one or more channels are employed.
  • the term “reservoir” generally refers to a designated area or chamber configured to retain a fluidic drug compound.
  • the reservoir may be an open volume space, gel, solid structure, etc. Nevertheless, in most embodiments, the reservoir is a solid matrix through which the drug compound is capable of flowing.
  • the selection of the desired materials for the matrix typically depends on the solubility and diffusivity of the target drug compound and the time during which release is sought.
  • the solid matrix is generally impermeable to the drug compound, and the material used to form the matrix is selected so that the drug compound is able to diffuse therethrough.
  • the solid matrix may be permeable or semi-permeable to the drug compound so that it can simply flow through its pores.
  • solid matrices include porous fiber webs (e.g., woven or nonwoven), apertured films, foams, sponges, etc.
  • polymeric materials are often used to form the solid matrix, such as silicones, acrylic resins, olefinic polymers (e.g., ethylene vinyl acetate), plasticized polyvinyl acetate/polyvinyl chloride resins, plasticized hydrolyzed polyvinyl alcohol, rubber-based adhesives (e.g., polyisobutylenes extended with a solvent such as mineral oil), plasticized polyvinyl chloride, polyethylene glycols and polypropylene glycols of varying molecular weights, cellulose esters, etc.
  • silicones e.g., silicones, acrylic resins, olefinic polymers (e.g., ethylene vinyl acetate), plasticized polyvinyl acetate/polyvinyl chloride resins, plasticized hydrolyzed polyvinyl alcohol, rubber-based adhesives (e.g., polyisobutylenes extended with a solvent such as mineral oil), plasticized polyvinyl chloride, polyethylene glycols and polypropy
  • a plurality of reservoirs may also be employed in certain embodiments for storing multiple materials for delivery.
  • the reservoirs may be positioned adjacent to each other, either in a vertical or horizontal relationship.
  • a first reservoir may contain a drug compound and a second reservoir may contain an excipient (e.g., delivery vehicle, such as alcohols, water, etc.; buffering agents; and so forth).
  • the first reservoir may contain a lyophilized powder of the drug compound and the second reservoir may contain an aqueous solution for reconstituting the powder.
  • each reservoir may be employed that each contains a drug compound.
  • the different materials may be mixed prior to delivery.
  • microneedle assembly and drug reservoir(s) may be integrated together in the form of a transdermal delivery device
  • the path may also contain other elements to help maintain the desired flow of the drug compound.
  • the drug reservoir may be in fluid communication with a rate control membrane that helps control the flow rate of the drug compound by modulating its pressure downstream from the reservoir.
  • the rate control membrane can help slow down the flow rate of the drug compound upon its release. Specifically, fluidic drug compounds passing from the drug reservoir to the microneedle assembly may experience a drop in pressure that results in a reduction in flow rate. If this difference is too great, some backpressure may be created that can impede the flow of the compound and potentially overcome the capillary pressure of the fluid through the microfluidic channels. Thus, the use of the rate control membrane can ameliorate this difference in pressure and allow the drug compound to be introduced into the microneedle at a more controlled flow rate.
  • the particular materials, thickness, etc. of the rate control membrane can vary based on multiple factors, such as the viscosity of the drug compound, the desired delivery time, etc.
  • the rate-controlling membrane may, for instance, include a permeable, semi-permeable or microporous material.
  • Suitable membrane materials include, for instance, fibrous webs (e.g., woven or nonwoven), apertured films, foams, sponges, etc., which are formed from polymers such as polyethylene, polypropylene, polyvinyl acetate, ethylene n-butyl acetate and ethylene vinyl acetate copolymers.
  • the transdermal delivery device may contain additional layers or materials that provide various benefits.
  • the assembly may include an adhesive layer that can help facilitate the attachment of the delivery device to a user’s skin during use.
  • the adhesive layer is often disposed over the reservoir.
  • the adhesive layer typically employs an adhesive coated onto a backing material.
  • the backing may be made of a material that is substantially impermeable to the drug compound, such as polymers, metal foils, etc. Suitable polymers may include, for instance, polyethylene terephthalate, polyvinylchloride, polyethylene, polypropylene, polycarbonate, polyester, and so forth.
  • the adhesive may be a pressure-sensitive adhesive as is known in the art.
  • Suitable adhesives may include, for instance, solvent-based acrylic adhesives, solvent-based rubber adhesives, silicone adhesives, etc.
  • a release member may also be positioned adjacent to the microneedle assembly so that it is adjacent to the support of the microneedle assembly and the optional rate control membrane. It should be understood, however, that the release layer need not contact such layers, and that other layers may be in fact be positioned between the release member and the support and/or rate control membrane.
  • the release member may contain a material that is substantially impermeable to the drug compound, such as a polymeric material, metal, etc. The material is also desirably hydrophobic. Suitable polymeric materials may include, for instance, polyethylene terephthalate, polyvinylchloride, polyethylene, polypropylene, polycarbonate, polyester, metal foils, and so forth.
  • the release member can initially seal the aperture in the support and thus limit the flow of the drug compound therethrough. In this manner, the release member may act as a barrier to the flow of the drug compound and thus inhibits premature leakage.
  • a force may be applied by the user to at least partially separate the release member, thereby breaking the seal.
  • the separation of the release member may be accomplished in a variety of ways. For instance, a portion of the release member may simply be separate (e.g., detached, ruptured, etc.).
  • the flow of the drug compound can be induced “passively” - i.e. , without the need for conventional active displacement mechanisms, such as liquid pumps, actuators, plungers, finger pressure, etc. This allows the delivery device to be placed on the skin before activation, thereby limiting potential spillage of the drug compound.
  • the passive delivery of the drug compound is also simple and easy to use, which enables it to be used by a wide variety of consumers, not just medical professionals.
  • Suitable compounds may include, for instance, proteinaceous compounds, such as insulin, immunoglobulins (e.g., IgG, IgM, IgA, IgE), TNF-a, antiviral medications, etc.; polynucleotide agents, such as plasmids, siRNA, RNAi, nucleoside anticancer drugs, vaccines, etc.; small molecule agents, such as alkaloids, glycosides, phenols, etc.; anti-infection agents, hormones, drugs regulating cardiac action or blood flow, pain control; vaccines; and so forth.
  • proteinaceous compounds such as insulin, immunoglobulins (e.g., IgG, IgM, IgA, IgE), TNF-a, antiviral medications, etc.
  • polynucleotide agents such as plasmids, siRNA, RNAi, nucleoside anticancer drugs, vaccines, etc.
  • small molecule agents such as alkaloids, glycosides, phenols
  • agents includes anti-Angiogenesis agents, anti-depressants, antidiabetic agents, antihistamines, anti-inflammatory agents, butorphanol, calcitonin and analogs, COX-II inhibitors, dermatological agents, dopamine agonists and antagonists, enkephalins and other opioid peptides, epidermal growth factors, erythropoietin and analogs, follicle stimulating hormone, glucagon, growth hormone and analogs (including growth hormone releasing hormone), growth hormone antagonists, heparin, hirudin and hirudin analogs such as hirulog, IgE suppressors and other protein inhibitors, immunosuppressives, insulin, insulinotropin and analogs, interferons, interleukins, leutenizing hormone, leutenizing hormone releasing hormone and analogs, monoclonal or polyclonal antibodies, motion sickness preparations, muscle relaxants, narcotic analgesics, nicotine, non-steroid anti
  • the microneedle assembly may be particularly beneficial in delivering high molecular weight drug compounds.
  • high molecular weight generally refers to compounds having a molecular weight of about 1 kiliDalton (“kDa”) or more, in some embodiments about 10 kDa or more, in some embodiments about 20 kDa to about 250 kDa, and in some embodiments, from about greater than about 40 kDa to about 150 kDa.
  • high molecular weight compounds include protein therapeutics, which refers to any biologically active proteinaceous compound including, without limitation, natural, synthetic, and recombinant compounds, fusion proteins, peptides, chimeras, and so forth, as well as compounds including the 20 standard amino acids and/or synthetic amino acids.
  • the drug compound may include a vaccine antigen, which is a substance that, when introduced to the body stimulates an immune response, such as T-cell activation and/or antibody production for prophylaxis against a virus.
  • Vaccine antigens may include natural intact pathogens (e.g., bacterium or virus), a live attenuated virus, or portions and/or subunits of a pathogen, such as a single virus or bacterium protein.
  • Vaccine antigens can also include cancer antigens or fragments thereof.
  • the vaccine antigen may be a coronavirus vaccine antigen that is used for prophylaxis against a coronavirus, such as SARS-CoV-1 ,
  • Such vaccine antigens may be derived from a coronavirus or other type of virus.
  • coronavirus vaccine antigens may include, for instance, mRNA-1273 (novel lipid nanoparticle (LNP)- encapsulated mRNA-based vaccine), BNT162 (LNP-encapsulated mRNA-based vaccine), Ad5-nCoV (recombinant adenovirus type-5 vector), ChAdOxl (adenovirus viral vector capable of producing the spike protein of SARS-CoV-2), bacTRL-Spike (live Bifidobacterium longum bacteria that have been engineered to deliver plasmids containing synthetic DNA encoding spike protein from SARS- CoV-2), BCG (prepared from a strain of the attenuated (virulence-reduced) live bovine tuberculosis bacillus, Mycobacterium bovis), AdCovid (intranasal vaccine),
  • LNP novel lipid nanoparticle
  • viral vaccine antigens may be derived from and/or used for prophylaxis against adenoviruses, arenaviruses, bunyaviruses, flavirviruses, hantaviruses, hepadnaviruses, herpesviruses, papilomaviruses, paramyxoviruses, parvoviruses, picornaviruses, poxviruses, orthomyxoviruses, retroviruses, reoviruses, rhabdoviruses, rotaviruses, spongiform viruses or togaviruses.
  • vaccine antigens may include peptides expressed by viruses, such as CMV, EBV, flu viruses, hepatitis A, B, or C, herpes simplex,
  • CMV vaccine antigens include envelope glycoprotein B and CMV pp65; EBV vaccine antigens include
  • hepatitis vaccine antigens include the S, M, and L proteins of hepatitis B virus, the pre-S antigen of hepatitis B virus, HBCAG
  • herpes simplex vaccine antigens include immediate early proteins and glycoprotein D
  • human immunodeficiency virus (HIV) vaccine antigens include gene products of the gag, pol, and env genes such as HIV gp32, HIV gp41 , HIV gp120, HIV gp160, HIV
  • human papillomavirus virus (HPV) viral antigens include the L1 protein
  • influenza vaccine antigens include hemagglutinin and neuraminidase
  • Japanese encephalitis vaccine antigens include proteins E, M-E, M-E-NS1, NS1, NS1-NS2A and 80% E
  • malaria vaccine antigens include the Plasmodium proteins circumsporozoite (CSP), glutamate dehydrogenase, lactate dehydrogenase, and fructose-bisphosphate aldolase
  • measles vaccine antigens include the measles virus fusion protein
  • rabies vaccine antigens include rabies glycoprotein and rabies nucleoprotein
  • respiratory syncytial vaccine antigens include the RSV fusion protein and the M2 protein
  • rotaviral vaccine antigens include VP7s
  • the microneedle assembly of the present invention is generally used to deliver a drug compound to a subject.
  • the microneedle assembly may also be employed as a sensor.
  • the microneedle assembly may be used only as a sensor, or in other cases, it may be used as a sensor to determine the dosage of the drug compound to delivery.
  • the microneedles may be placed into contact with the skin of a subject and allowed to remain for a period of time sufficient to contact a bodily fluid (e.g., blood) from the subject that contains an analyte of interest. The fluid may be withdrawn and tested.
  • a bodily fluid e.g., blood
  • a detection system can be coupled to the microneedle assembly, such as incorporated on an external surface of the microneedles (e.g., solid microneedles) or within the interior of the microneedles (e.g., microneedles with hollow channels), so that the fluid can simply be allowed to contact the microneedles for testing.
  • Various examples of such sensors are known in the art and described, for instance, in U.S. Patent Publication Nos. 2020/0015751 to Chickerinq et al. and 2013/0225956 to Huang, et al., which are incorporated herein in their entirety by reference thereto.
  • target analytes examples include, but are not limited to, pH or metal ions, proteins, nucleic acids (e.g., DNA,
  • RNA RNA, etc.
  • drugs e.g., glucose
  • hormones e.g., estradiol, estrone, progesterone, progestin, testosterone, androstenedione, etc.
  • carbohydrates or other analytes of interest.
  • Other conditions that can be determined can include pH changes, which may indicate disease, yeast infection, periodontal disease at a mucosal surface, oxygen or carbon monoxide levels which indicate lung dysfunction, and drug levels, e.g., legal prescription levels of drugs such as coumadin, other drugs such as nicotine, or illegal drugs such as cocaine.
  • analytes include those indicative of disease, such as cancer specific markers such as CEA and PSA, viral and bacterial antigens, and autoimmune indicators, such as antibodies to double stranded DNA. Still other conditions include exposure to elevated carbon monoxide, which could be from an external source or due to sleep apnea, too much heat (important in the case of babies whose internal temperature controls are not fully self-regulating) or from fever.
  • Other potentially suitable analytes include various pathogens, such as bacteria or viruses, and/or markers produced by such pathogens.
  • the senor may contain an antibody able to interact with a marker for a disease state, an enzyme such as glucose oxidase or glucose 1 -dehydrogenase able to detect glucose, or the like.
  • an enzyme such as glucose oxidase or glucose 1 -dehydrogenase able to detect glucose, or the like.
  • the analyte may be determined quantitatively or qualitatively, and/or the presence or absence of the analyte within the withdrawn fluid may be determined in certain cases.
  • the particular detection system used in combination with the microneedle assembly to detect the analyte can vary as understood by those skilled in the art.
  • various non-limiting examples of sensor techniques include pressure or temperature measurements, spectroscopy such as infrared, absorption, fluorescence, UV/visible, FTIR ("Fourier Transform Infrared
  • the senor may rely upon electrochemical impedance for detection and thus include at least one working electrode, which is typically positioned on, within, or otherwise in fluidic contact with a first microneedle.
  • the working electrode may be a metal (e.g., gold) that is deposited on a surface of the microneedle.
  • the sensor may also include at least one reference electrode positioned on, within, or otherwise in fluidic contact with a second microneedle and/or at least one counter electrode positioned on, within and/or otherwise in fluidic contact with a third microneedle.
  • the reference and counter electrodes may also be made of a metal (e.g., gold) deposited on a surface of respective microneedles. Impedance values may be detected to evaluate the concentration of the analyte. If desired, the sensitivity of the detection system can be enhanced through the accumulation of a trace amount of target molecules at the electrode.
  • the microneedles may be subjected to surface modification, such as with an enzyme, an antibody, an aptamer, a single-chain variable fragment (ScFv), a carbohydrate, and a combination thereof.
  • the working electrodes may be modified with glucose oxidase (GOx) for glucose detection.
  • GOx glucose oxidase
  • melt Viscosity The melt viscosity (Pa-s) may be determined in accordance with ISO Test No. 11443:2005 at a shear rate of 400 s 1 or 1,000 s 1 and temperature 15°C above the melting temperature (e.g., about 350°C) using a Dynisco LCR7001 capillary rheometer.
  • the rheometer orifice (die) had a diameter of 1 mm, length of 20 mm, L/D ratio of 20.1, and an entrance angle of 180°.
  • the diameter of the barrel was 9.55 mm + 0.005 mm and the length of the rod was 233.4 mm.
  • Tm The melting temperature
  • DSC differential scanning calorimetry
  • the melting temperature is the differential scanning calorimetry (DSC) peak melt temperature as determined by ISO Test No. 11357-2:2013. Under the DSC procedure, samples were heated and cooled at 20°C per minute as stated in ISO
  • DTUL Deflection Temperature Under Load
  • test strip sample having a length of 80 mm, thickness of 10 mm, and width of 4 mm may be subjected to an edgewise three-point bending test in which the specified load (maximum outer fibers stress) was 1.8 Megapascals.
  • the specimen may be lowered into a silicone oil bath where the temperature is raised at 2°C per minute until it deflects 0.25 mm (0.32 mm for ISO Test No. 75-2:2013).
  • Tensile Modulus, Tensile Stress, and Tensile Elongation Tensile properties may be tested according to ISO Test No. 527:2012 (technically equivalent to ASTM D638-14). Modulus and strength measurements may be made on the same test strip sample having a length of 80 mm, thickness of 10 mm, and width of 4 mm. The testing temperature may be 23°C, and the testing speeds may be 1 or 5 mm/min.
  • Flexural Modulus, Flexural Stress, and Flexural Elongation Flexural properties may be tested according to ISO Test No. 178:2010 (technically equivalent to ASTM D790-10). This test may be performed on a 64 mm support span. Tests may be run on the center portions of uncut ISO 3167 multi-purpose bars. The testing temperature may be 23°C and the testing speed may be 2 mm/min.
  • Unnotched and Notched Charpy Impact Strength Charpy properties may be tested according to ISO Test No. ISO 179-1:2010) (technically equivalent to ASTM D256-10, Method B). This test may be run using a Type 1 specimen size (length of 80 mm, width of 10 mm, and thickness of 4 mm). When testing the notched impact strength, the notch may be a Type A notch (0.25 mm base radius). Specimens may be cut from the center of a multi-purpose bar using a single tooth milling machine. The testing temperature may be 23°C.
  • Samples 1-5 and a Control sample are formed for use in a microneedle assembly.
  • the samples contained various combinations of a liquid crystalline polymer (LCP 1 of LCP 2), talc (TALC 1 or TALC 2), and/or polytetrafluoroethylene (PTFE).
  • LCP 1 is formed from 60% FIBA, 4% HNA, 18% BP, and 18% TA.
  • LCP 2 is formed from 48% HNA, 2% HBA, 25% BP, and 25% TA.
  • TALC 1 had a median particle size of 4 micrometers and TALC 2 had a median particle size of 1 micrometer.
  • Compounding was performed using an 18- mm single screw extruder. Samples are injection molded into plaques (60 mm x 60 mm). The formulations are set forth below.
  • Samples 6-10 are formed for use in a microneedle assembly.
  • the samples contained various combinations of a liquid crystalline polymer (LCP 2), talc (TALC 1 or TALC 2), and/or polytetrafluoroethylene (PTFE).
  • LCP is formed from 48% HNA, 2% HBA, 25% BP, and 25% TA. Compounding was performed using an 18-mm single screw extruder. Samples are injection molded into plaques (60 mm x 60 mm). The formulations are set forth below.

Abstract

L'invention concerne un ensemble micro-aiguille qui est capable d'administrer un composé médicamenteux (par exemple, un vaccin) et/ou de détecter la présence d'un analyte. L'ensemble comprend au moins une micro-aiguille s'étendant vers l'extérieur à partir d'un support. La micro-aiguille comprend une composition polymère contenant un polymère thermoplastique ayant une température de fusion d'environ 250°C ou plus. La composition polymère présente une viscosité à l'état fondu d'environ 100 Pa-s ou moins et un allongement à la traction d'environ 5% ou moins.
EP21796676.1A 2020-04-28 2021-04-21 Ensemble micro-aiguille Pending EP4142828A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063016560P 2020-04-28 2020-04-28
US202063034429P 2020-06-04 2020-06-04
PCT/US2021/028350 WO2021221972A1 (fr) 2020-04-28 2021-04-21 Ensemble micro-aiguille

Publications (2)

Publication Number Publication Date
EP4142828A1 true EP4142828A1 (fr) 2023-03-08
EP4142828A4 EP4142828A4 (fr) 2024-04-10

Family

ID=78221521

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21796676.1A Pending EP4142828A4 (fr) 2020-04-28 2021-04-21 Ensemble micro-aiguille

Country Status (7)

Country Link
US (1) US20210330951A1 (fr)
EP (1) EP4142828A4 (fr)
JP (1) JP2023523908A (fr)
CN (1) CN115734793A (fr)
AU (1) AU2021264950A1 (fr)
BR (1) BR112022022057A2 (fr)
WO (1) WO2021221972A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3431133B1 (fr) * 2016-03-16 2022-04-20 Cosmed Pharmaceutical Co., Ltd. Boîtier de timbre à micro-aiguilles

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040135118A1 (en) * 2002-12-18 2004-07-15 Waggoner Marion G. Process for producing a liquid crystalline polymer
US7658728B2 (en) * 2006-01-10 2010-02-09 Yuzhakov Vadim V Microneedle array, patch, and applicator for transdermal drug delivery
US7785301B2 (en) * 2006-11-28 2010-08-31 Vadim V Yuzhakov Tissue conforming microneedle array and patch for transdermal drug delivery or biological fluid collection
ES2358132T3 (es) * 2007-08-24 2011-05-05 Ems-Patent Ag Masas moldeadas de poliamida a alta temperatura reforzadas con fibras de vidrio planas.
KR101798255B1 (ko) * 2009-12-18 2017-11-15 쓰리엠 이노베이티브 프로퍼티즈 컴파니 열방성 액정 중합체의 성형 및 이로부터 제조된 용품
US20130158482A1 (en) * 2010-07-26 2013-06-20 Seventh Sense Biosystems, Inc. Rapid delivery and/or receiving of fluids
CA2857501C (fr) * 2011-11-30 2020-06-23 3M Innovative Properties Company Dispositif a micro-aiguille comprenant un agent therapeutique peptidique et un acide amine et procedes de fabrication et d'utilisation de celui-ci

Also Published As

Publication number Publication date
CN115734793A (zh) 2023-03-03
WO2021221972A1 (fr) 2021-11-04
JP2023523908A (ja) 2023-06-08
EP4142828A4 (fr) 2024-04-10
AU2021264950A1 (en) 2022-11-03
US20210330951A1 (en) 2021-10-28
BR112022022057A2 (pt) 2022-12-13

Similar Documents

Publication Publication Date Title
US10406339B2 (en) Force-controlled applicator for applying a microneedle device to skin
Demir et al. Characterization of polymeric microneedle arrays for transdermal drug delivery
CA2796965C (fr) Procede d'augmentation de la permeabilite d'une barriere epitheliale
US9545737B2 (en) System and method for producing particles and patterned films
US20210330951A1 (en) Microneedle Assembly
EP2450079B1 (fr) Matériau de type aiguille
US20210330952A1 (en) Microneedle Assembly
JP2009502261A (ja) マイクロアレイデバイス
KR20150100807A (ko) 치료제의 전달을 위한 마이크로어레이 및 그것의 사용방법
JP2014519385A (ja) マイクロニードルを含む経皮装置
KR20120037910A (ko) 마이크로니들 어레이
CN104027324A (zh) 一种可溶性微针疫苗贴片及其制备方法
Hou et al. Up-to-date vaccine delivery systems: robust immunity elicited by multifarious nanomaterials upon administration through diverse routes
Deming Synthesis and self-assembly of well-defined block copolypeptides via controlled NCA polymerization
CN108939283B (zh) 一种人体安全可降解的微针阵列及其制造方法和模具
EP3275500B1 (fr) Micro-aiguille et son procédé de production
Bai et al. Dissolving microneedles for transdermal drug delivery system
US20230059289A1 (en) Drug Delivery Pump
Sonowal et al. Studies on In-Situ forming thermo sensitive injectable polymeric gel for sustained drug delivery
Tarbox Dissolving and coated microneedles as useful drug delivery platforms

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221020

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230525

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240307

RIC1 Information provided on ipc code assigned before grant

Ipc: A61B 5/00 20060101ALI20240301BHEP

Ipc: A61B 5/1486 20060101ALI20240301BHEP

Ipc: A61L 31/16 20060101ALI20240301BHEP

Ipc: A61L 31/14 20060101ALI20240301BHEP

Ipc: A61L 31/12 20060101ALI20240301BHEP

Ipc: A61L 31/04 20060101ALI20240301BHEP

Ipc: A61B 5/145 20060101ALI20240301BHEP

Ipc: A61K 9/00 20060101ALI20240301BHEP

Ipc: A61M 37/00 20060101ALI20240301BHEP

Ipc: A61M 5/158 20060101AFI20240301BHEP